Company research
Vyome Holdings, Inc
CIK 1427570Updated Sep 25, 2026
SecurityHIND · NASDAQ · equity
Name history
ReShape Lifesciences Inc. · through Aug 14, 2025OBALON THERAPEUTICS INC · through Jun 21, 2021
HIND price & chart
Loading TradingView…
NASDAQ:HIND on TradingView ↗About the company
Vyome is building the world’s premier platform spanning the US-India innovation corridor. Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.
In the news
No coverage from other publishers is available.
Recent filings
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 6,497,177Source | 4,793,000Source | 10,663,000Source | 11,142,000Source |
| Property, Plant and Equipment, NetUSD | 46,393Source | 38,000Source | 60,000Source | 698,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 314,191Source | — | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,982,333Source | 693,000Source | 4,459,000Source | 3,855,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 325Source | 1,000,000Source | 1,700,000Source | — |
| Inventory, NetUSD | — | 2,460,000Source | 3,741,000Source | 3,611,000Source |
| Assets, CurrentUSD | 5,438,321Source | 4,588,000Source | 10,296,000Source | 9,911,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | — | 348,000Source | 337,000Source | 165,000Source |
| Operating Lease, Right-of-Use AssetUSD | 29,428Source | 116,000Source | 250,000Source | 171,000Source |
| Other Assets, NoncurrentUSD | — | 29,000Source | 29,000Source | 46,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,735,160Source | 5,046,000Source | 4,000,000Source | 7,481,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 5,919Source | — | 23,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 90,078,579Source | 642,555,000Source | 642,302,000Source | 627,935,000Source |
| Retained Earnings (Accumulated Deficit)USD | -87,563,575Source | -642,704,000Source | -635,574,000Source | -624,187,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -78,864Source | -104,000Source | -88,000Source | -88,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | -253,000Source | 6,663,000Source | 3,661,000Source |
| Liabilities and EquityUSD | 6,497,177Source | 4,793,000Source | 10,663,000Source | 11,142,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,735,160Source | 4,985,000Source | 3,777,000Source | 7,481,000Source |
| Operating Lease, Liability, CurrentUSD | 31,258Source | 115,000Source | 111,000Source | 171,000Source |
| Accounts Payable, CurrentUSD | 647,533Source | 2,208,000Source | 1,689,000Source | 1,926,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 41,000Source | 151,000Source | — |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 1,319,958Source | — | — | — |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 639,150Source | 1,688,000Source | 1,814,000Source | 5,040,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -10,477,713Source | -7,130,000Source | -11,387,000Source | -46,214,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 577,128Source | 184,000Source | 766,000Source | 2,087,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | — | -922,000Source | 465,000Source | 1,187,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | 6,000Source | 28,000Source | -423,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -3,748,853Source | -4,427,000Source | -16,960,000Source | -21,902,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | -10,000Source | -92,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 8,654,976Source | 677,000Source | 17,574,000Source | 3,130,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 4,880,429Source | -3,766,000Source | 604,000Source | -18,860,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 4,982,333Source | 793,000Source | 4,559,000Source | 3,955,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | — | 12,000Source | 10,000Source | 5,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 577,128Source | 184,000Source | 767,000Source | 2,087,000Source |
| Amortization of Deferred ChargesUSD | — | 103,000Source | — | — |
| Amortization of Intangible AssetsUSD | — | 0Source | 33,000Source | 1,823,000Source |
| DepreciationUSD | — | 22,000Source | 121,000Source | 330,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | -51,000Source | 22,000Source | -141,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | 33,000Source | -529,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | 429,000Source | — | — |
| General and Administrative ExpenseUSD | — | 6,931,000Source | 10,324,000Source | 17,250,000Source |
| Goodwill and Intangible Asset ImpairmentUSD | — | — | — | 18,744,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 777,000Source | 18,744,000Source |
| Income Tax Expense (Benefit)USD | — | 39,000Source | 52,000Source | -380,000Source |
| InterestExpenseNonoperatingUSD | 146,641Source | — | — | — |
| Inventory Write-downUSD | — | 359,000Source | 335,000Source | 579,000Source |
| Net Income (Loss) Attributable to ParentUSD | -10,262,007Source | -7,130,000Source | -11,387,000Source | -46,214,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -215,706Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,387,000Source | -46,214,000Source |
| Nonoperating Income (Expense)USD | -25,143Source | — | — | — |
| Operating ExpensesUSD | 10,671,341Source | 12,785,000Source | 20,931,000Source | 53,153,000Source |
| Operating Lease, Impairment LossUSD | — | 36,000Source | — | — |
| Other Nonoperating Income (Expense)USD | 90,987Source | 193,000Source | 122,000Source | 11,000Source |
| Proceeds from Issuance of Common StockUSD | 1,282,653Source | — | 13,438,000Source | 639,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | — | 8,006,000Source | 8,678,000Source | 11,240,000Source |
| Cost of RevenueUSD | 100,943Source | 2,949,000Source | 3,130,000Source | 4,438,000Source |
| Selling, General and Administrative ExpenseUSD | 2,365,565Source | — | 7,548,000Source | 14,093,000Source |
| Operating Income (Loss)USD | -10,452,570Source | -7,728,000Source | -15,383,000Source | -46,351,000Source |
| Other Nonoperating Income (Expense)USD | 90,987Source | 193,000Source | 122,000Source | 11,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | -7,091,000Source | -11,335,000Source | -46,594,000Source |
| Income Tax Expense (Benefit)USD | — | 39,000Source | 52,000Source | -380,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -215,706Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -10,262,007Source | -7,130,000Source | -11,387,000Source | -46,214,000Source |
| Earnings Per Share, BasicUSD per share | -4.86Source | -13.83Source | -1.91Source | -108.9Source |
| Earnings Per Share, DilutedUSD per share | -4.86Source | -13.83Source | -1.91Source | -108.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 2,161,342Source | 515,566Source | 5,956,549Source | 424,390Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 2,161,342Source | 515,566Source | 5,956,549Source | 424,390Source |
| Interest Expense (non-operating)USD | 146,641Source | — | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | 0Source | 33,000Source | 1,823,000Source |
| Business Combination, Acquisition Related CostsUSD | — | 1,024,000Source | — | — |
| Debt Securities, Gain (Loss)USD | 30,511Source | — | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 11,985Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | -51,000Source | 22,000Source | -141,000Source |
| General and Administrative ExpenseUSD | — | 6,931,000Source | 10,324,000Source | 17,250,000Source |
| Gross ProfitUSD | 218,771Source | 5,057,000Source | 5,548,000Source | 6,802,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | 14,000Source | 26,000Source | -113,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -11,387,000Source | -46,214,000Source |
| Nonoperating Income (Expense)USD | -25,143Source | — | — | — |
| Operating ExpensesUSD | 10,671,341Source | 12,785,000Source | 20,931,000Source | 53,153,000Source |
| Other ExpensesUSD | 116,900Source | — | — | — |
| Research and Development ExpenseUSD | 588,258Source | 1,803,000Source | 2,315,000Source | 2,537,000Source |
| Selling and Marketing ExpenseUSD | — | 2,991,000Source | — | — |
Offerings
Registration 333-282459
Registration 333-284362
Registration 333-283952
Filing attachments
ea030322801ex99-1.htm · 8-K · 2026-08-25
EX-99.1 2 ea030322801ex99-1.htm PRESS RELEASE DATED AUGUST 25, 2026 Exhibit 99.1 Vyome Holdings Reports Second Quarter 2026 Results Highlighted By Advancement Of Lead VT-1953 Program, Pipeline Expansion And Strong Balance Sheet CAMBRIDGE, Mass., August 25, 2026 - Vyome Holdings, Inc. (“Vyome”), a clinical-stage biopharmaceutical company focused on immuno-inflammatory and rare disease conditions, today reports financial results for the second quarter ended June 30, 2026, and provides a corp…
Read attachment ↗ea029264301ex99-1.htm · 8-K · 2026-05-29
EX-99.1 2 ea029264301ex99-1.htm PRESS RELEASE DATED MAY 28, 2026 Exhibit 99.1 Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet Vyome has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1 VT-1953 regulatory submissions to the FDA for Orphan Drug Designation status and proposals for constructive FDA gui…
Read attachment ↗ea027793501ex99-1_vyome.htm · 8-K · 2026-02-25
EX-99.1 3 ea027793501ex99-1_vyome.htm PRESS RELEASE ISSUED FEBRUARY 24, 2026 Exhibit 99.1 Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026 CAMBRIDGE, MA - Livechain, Inc (“Livechain”) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc (“Vyome”) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, …
Read attachment ↗ea027697501ex99-1_vyome.htm · 8-K · 2026-02-13
EX-99.1 2 ea027697501ex99-1_vyome.htm VT-1953 PHASE 2 DATA PRESENTATION Exhibit 99.1 VT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS © Vyome Holdings, Inc. February 2026 VYOME HOLDINGS, INC. (“Vyome”) 2 Any statements contained in this presentation that do not describe historical facts may constitute forward - looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be …
Read attachment ↗ea027436701ex99-1_vyome.htm · 8-K · 2026-01-28
EX-99.1 2 ea027436701ex99-1_vyome.htm PRODUCT ASSESSMENT AND VALUATION REPORT Exhibit 99.1 1 U.S. Market & Product Assessment and Valuation of VT - 1953 for the Treatment of Symptoms of Malignant Fungating Wounds H1 2026 2 PROJECT OVERVIEW Destum Partners performed a U.S. market and product assessment, commercial forecast, and valuation for the use of VT - 1953 for the treatment of symptoms of Malignant Fungating Wounds (MFW) Commercial Forecast Market & Product Assessment ▪ Epidemiology ▪…
Read attachment ↗ea027436701ex99-2_vyome.htm · 8-K · 2026-01-28
EX-99.2 3 ea027436701ex99-2_vyome.htm PRESS RELEASE ISSUED JANUARY 27, 2026 Exhibit 99.2 Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion Modeled peak annual U.S. sales approaching USD 600 million for VT-1953 Independent valuation analysis estimates post-Phase 3 asset value approaching USD 1 billion, and the current valuat…
Read attachment ↗